Comparison of survival analyses in astrocytomas according to the classifications used. Kaplan–Meier estimates of progression‐free survival (PFS) and OS for astrocytomas according to histo‐molecular classifications. Concerning Grade 2 astrocytomas, the median PFS and OS were longer in patients with AII‐IDHmut (WHO 2016 classification with cIMPACT‐NOW update 3 and our integrated classification) (35.9 and 98.8 months, respectively), than in patients with AII (WHO 2007 classification) (24.0 and 66.3 months, respectively), and than in patients with AII‐IDHwt (WHO 2016 classification) (8.1 and 21.2 months, respectively). Concerning Grade 3 anaplastic astrocytomas, the median PFS was longer in patients with AIII‐IDHmut (our integrated classification) (33.9 months), than in patients with AIII‐IDHwt (our integrated classification) (32.6 months), than in patients with AIII‐IDHmut (WHO 2016 classification & WHO 2016 classification with cIMPACT‐NOW update 3) (30.5 months), than in patients with AIII‐IDHwt (WHO 2016 classification with cIMPACT‐NOW update 3) (21.4 months), than in patients with AIII (WHO 2007) (9.2 months), and than in patients with AIII‐IDHwt (WHO 2016 classification) (9.0 months). The median OS was longer in patients with AIII‐IDHmut (our integrated classification) (not reached), than in patients with AIII‐IDHmut (WHO 2016 classification & WHO 2016 classification with cIMPACT‐NOW update 3) (70.8 months), than in patients with AIII‐IDHwt (our integrated classification) (29.0 months), than in patients with AIII (WHO 2007) (18.8 months), than in patients with AIII‐IDHwt (WHO 2016 classification) (11.0 months), than in patients with AIII‐IDHwt (WHO 2016 classification with cIMPACT‐NOW update 3) (8.1 months)